Lightbridge Corporation Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity and Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2019

	June 30,		December 31,
*Outstanding Warrants*	2019		2018
Issued to Investors on October 25, 2013, entitling the holders to purchase 250,000 common shares in the Company at an exercise price of $11.50 per common share up to and including April 24, 2021. In 2016, 59,450 of these warrants were exchanged for common stock, and all remaining warrant holders agreed to new warrant terms, which excluded any potential net cash settlement provisions in exchange for a reduced exercise price of $6.25 per share.		163,986		163,986

Issued to Investors on November 17, 2014, entitling the holders to purchase 546,919 common shares in the Company at an exercise price of $11.55 per common share up to and including May 16, 2022. On June 30, 2016, the warrant holders agreed to new warrant terms, which excluded any potential net cash settlement provisions in order to classify them as equity in exchange for a reduced exercise price of $6.25 per share.		546,919		546,919

Issued to an investment bank and subsequently transferred to a principal of the investment bank regarding the Series B Preferred Stock investment on January 30, 2018, entitling the holder to purchase 133,432 common shares in the Company at an exercise price of $1.50 per share, up to and including January 30, 2021.		133,432		133,432
Total		844,337		844,337

	Three Months Ended June 30,		Six Months Ended June 30,
	2019	2018	2019	2018

Research and development expenses	$ 113,488	$ 63,118	$ 283,622	$ 566,335
General and administrative expenses	123,784	85,592	288,663	855,410
Total stock-based compensation expense	$ 237,272	$ 148,710	$ 572,285	$ 1,421,745

Expected volatility		90	%
Risk free interest rate		2.84	%
Dividend yield rate		0	%
Weighted average years	9.8 months
Closing price per share – common stock	$	0.88

Stock option transactions to the employees, directors and consultants are summarized as follows for the six months ended June 30, 2019:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value
Beginning of the period		5,604,154		$	2.72	$	1.96
Granted		—			—		—
Exercised		—			—		—
Forfeited		(218,096	)		2.86		2.13
Expired		(161,338	)		14.74		11.04
End of the period		5,224,720		$	2.35	$	1.67

Options exercisable		3,555,704		$	3.03	$	2.13

Stock option transactions of the employees, directors, and consultants are summarized as follows for the year ended December 31, 2018:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value
Beginning of the year		3,976,884		$	3.58	$	2.49
Granted		1,784,455			0.90		0.70
Exercised		—			—		—
Forfeited		(143,980	)		1.10		0.83
Expired		(13,205	)		30.60		21.13
End of the year		5,604,154		$	2.72	$	1.96

Options exercisable		3,935,138		$	3.50	$	2.49

	Shares			Weighted- Average Fair Value Grant Date		Weighted Average Exercise Price

Non-vested – December 31, 2017		1,542,736		$	1.10	$	1.58
Granted		1,784,455			0.70		0.90
Vested		(1,514,195	)		1.27		1.58
Forfeited		(143,980	)		0.83		1.10
Non-vested – December 31, 2018		1,669,016		$	0.54	$	0.91

Granted		—			—		—
Vested		—			—		—
Forfeited		—			—		—
Non-vested – June 30, 2019		1,669,016		$	0.54	$	0.91